Syneos Health, Inc. (SYNH) Prices 7M Secondary Offering at $59.75/Sh

Syneos Health, Inc. (NASDAQ: SYNH), the only fully integrated biopharmaceutical solutions organization combining a CRO (Contract Research Organization) and a CCO (Contract Commercial Organization), today announced the pricing of the previously announced underwritten secondary offering by affiliates of Thomas H. Lee Partners, L.P. and Advent International Corporation of an aggregate of 7,000,000 shares of the Company’s common stock (the “Offering”) at a price to the public of $59.75 per share. Syneos Health is not selling and will not receive any proceeds from the proposed sale of the shares by the selling stockholders in this Offering. The Offering is expected to close on September 17, 2020, subject to customary closing conditions. The Company has agreed to repurchase from the underwriters approximately $30 million in aggregate of the shares of common stock being sold by the selling stockholders at a per-share purchase price equal to the price payable by the underwriters to the selling stockholders.

Goldman Sachs & Co. LLC and Morgan Stanley are acting as the underwriters of the Offering.

You May Also Be Interested In

• Goldman Sachs Adjust Monthly US Director's Cut List
• NU E Power Corp. adds Peter Espig to its board of directors
• BiomX to rename itself Tessera Defense, ticker changes to HLSQ